Fuzionaire Theranostics announces GRPR-targeting theranostic program for metastatic prostate cancer

Aug. 1, 2023

Fuzionaire Diagnostics Inc. has changed its name to Fuzionaire Theranostics Inc. to better reflect the company’s pipeline of paired fluorine-18 PET diagnostics and radioligand therapies to find and treat cancer.

BioWorld Science Cancer Diagnostics

Today's news in brief

BioWorld

BioWorld briefs for Oct. 15, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for October 15, 2024.

Visualization of protein folding process

Protein design: if you can’t find ’em, make ’em

BioWorld

David Baker, director of the Institute for Protein Design at the University of Washington School of Medicine, is a pioneer in protein design. His contributions...

FDA gives early nod to Genentech’s first-line breast cancer drug

BioWorld

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the...

Gilead ends $785M Yuhan deal for small-molecule MASH drugs

BioWorld

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis...

Upgrade your daily dose of biopharma and medtech news

Fuzionaire Theranostics announces GRPR-targeting theranostic program for metastatic prostate cancer